Big Drug Companies Like Valeant Serve Shareholders at the Expense of Public Health

The price of life should not be justification for quadrupling the price of life-saving drugs to make people billionaires. Valeant Pharmaceuticals International’s J. Michael Pearson has a habit of buying up existing drugs and raising prices by insane proportions, keeping the profit to reward shareholders or personal gain instead of investing the money to developing new drugs. The United States does not control drug prices, which explains how the price of drugs can increase by 800% in under one month. Some insurers have dropped coverage of drugs with dramatically increased prices.

It’s important to have representatives who put the interest of taxpayers and patients over those of drug companies. Otherwise, you may have politicians who spend $400,000 in travel bills for chartered flights.